National Center for Complementary & Alternative Medicine; Notice of Closed Meeting, 55073-55074 [2011-22695]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 172 / Tuesday, September 6, 2011 / Notices
represents a valid approach to inhibit
tumor growth.
The present invention discloses the
identification and characterization of a
fully human monoclonal antibody
designated m708.5 that has been affinity
maturated against IGF–I and IGF–II and
displays extremely high affinities for
IGF–I and IGF–II in the picoM range.
The m708.5 antibody potently inhibited
signal transduction mediated by the
IGF–1R interaction with IGF–I and
IGF–II and blocked phosphorylation of
IGF–IR and the insulin receptor.
Further, this antibody inhibited
migration in the MCF–7 breast cancer
cell line at the picoM range. Therefore,
this antibody can be used to prevent
binding of IGF–I and/or IGF–II to its
concomitant receptor IGFIR,
consequently, modulating diseases such
as cancer.
Potential Commercial Applications:
• Therapeutic for the treatment of
various human diseases associated with
aberrant cell growth and motility such
as breast, prostate, and leukemia
carcinomas.
• Research regent to study IGF–I and/
or IGF–II binding and its association
with tumor growth.
Competitive Advantages:
• Antibodies against the ligands
IGF–I and IGF–II, such as this invention,
inhibit the interaction with IGF–IR yet
likely do not have the type of toxicity
associated with IGF–1R antibodies.
• High concentrations of IGF–II are
found in cancer patients, on average
several fold higher than IGF–I, thus this
cross-reacting IGF–I/IGF–II antibody
could be more effective than existing
IGF–IR and/or IGF–I currently in the
clinic.
• This novel IGF antibody may
provide therapeutic intervention for
multiple carcinomas.
Development Stage:
• Pre-clinical.
• In vitro data available.
Inventors: Dimiter Dimitrov, Zhongyu
Zhu, and Qi Zhao (NCI).
Publications:
1. Zhao Q, et al. Human monoclonal
antibody fragments binding to insulinlike growth factors 1 and 2 with
picomolar affinity. Mol Cancer Ther.
2011 Jul 12; Epub ahead of print. [PMID
21750218].
2. Feng Y, et al. Novel human
monoclonal antibodies to insulin-like
growth factor (IGF)–II that potently
inhibit the IGF receptor type I signal
transduction function. Mol Cancer Ther.
2006;5(1):114–120. [PMID 18283605].
3. Kimura T, et al. Targeting of bonederived insulin-like growth factor-II by
a human neutralizing antibody
suppresses the growth of prostate cancer
VerDate Mar<15>2010
18:00 Sep 02, 2011
Jkt 223001
cells in a human bone environment.
Clin Cancer Res. 2010 Jan 1;16(1): 121–
129. [PMID 20028742].
Intellectual Property: HHS Reference
No. E–068–2011/0—U.S. Provisional
Application No. 61/474,664 filed 12
April 2011.
Related Technologies:
• HHS Reference No. E–336–2005/
0—U.S. Patent Application No. 12/
296,328 filed 07 Oct 2008; Antibody
Compositions and Methods for
Treatment of Neoplastic Disease.
• HHS Reference No. E–217–2005/
0—U.S. Patent No. 7,824,681 issued 02
Nov 2010; Human Monoclonal
Antibodies that Specifically Bind IGF–
II.
Licensing Contact: Whitney Hastings;
301–451–7337; hastingw@mail.nih.gov.
Collaborative Research Opportunity:
The NCI CCR Nanobiology Program,
Protein Interaction Group, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact John Hewes, PhD at
hewesj@mail.nih.gov.
Transgenic Mice Expressing Human
Arginase II Gene in Endothelium:
Useful for Studying Atherosclerosis and
Other Vasculopathies
Description of Technology:
Cardiovascular disorders associated
with endothelial dysfunction, like
atherosclerosis, have decreased
endothelial nitric oxide (NO)
bioavailability. L-arginine, the primary
substrate for endothelial nitric oxide
synthase (eNOS), is important in the
regulation of NO production. Arginase
competes with eNOS for L-arginine and
has been implicated in the endothelial
dysfunction. NIH investigators have
generated transgenic mice with human
ArgII (hArgII) gene under control of
endothelial-specific Tie2 promoter. In
these mice, hArgII was expressed at very
high levels in all tissues except liver.
Analysis has shown that expression of
hArgII was endothelium-specific.
Overexpression of hArgII neither led to
significant changes in plasma level of
arginine, citrulline, NOHA, ADMA,
SDMA and ornithine, nor to changes in
plasma lipid levels. Level of arginase
activity in peritoneal macrophages
isolated from the transgenic mice also
was also unchanged. However, ArgII
overexpression induced signs of
endothelial dysfunction. In apoEknockout mice hArgII led to 2-fold
increasing in aortic area with
atherosclerotic lesions. The Tie2hArgII
transgenic mouse can be useful as a new
model for investigating the role of ArgII
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
55073
in endothelial function and
development of atherosclerosis.
Potential Commercial Applications:
• Useful to study the role of arginase
II gene in endothelium.
• Useful for testing the drugs for
treatment of the endothelial dysfunction
related to eNOS insufficiency, including
hypertension.
• Useful to study mechanisms of
atherosclerosis.
Competitive Advantages: Better model
system to study functional significance
of arginase II.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vivo data available (animal).
Inventors: Boris L. Vaisman and Alan
T. Remaley (NHLBI).
Publication: Vaisman BL, et al.
Abstract 3636: The Effects of Arginase II
Overexpression on Endothelial Function
in Transgenic Mouse Model.
Circulation. 2008 Oct 28;118:S_455.
Intellectual Property: HHS Reference
No. E–255–2010/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Suryanarayana
(Sury) Vepa, PhD; 301–435–5020;
vepas@mail.nih.gov.
Dated: August 29, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–22694 Filed 9–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Alternative Medicine; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the National Advisory
Council for Complementary and
Alternative Medicine (NACCAM)
meeting.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\06SEN1.SGM
06SEN1
55074
Federal Register / Vol. 76, No. 172 / Tuesday, September 6, 2011 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications
and/or contract Proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable materials, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Complementary and Alternative
Medicine.
Date: October 14, 2011.
Closed: October 14, 2011, 8:30 to 10:30
a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Open: October 14, 2011, 11 a.m. to 4 p.m.
Agenda: Opening remarks by the Director
of the National Center for Complementary
and Alternative Medicine, presentation of a
new research initiative, and other business of
the Council.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen, PhD,
Executive Secretary, Director, Division of
Extramural Activities, National Center for
Complementary and Alternative Medicine,
National Institutes of Health, 6707
Democracy Blvd., Suite 401, Bethesda, MD
20892, (301) 594–2014.
The public comments session is scheduled
from 3:30 to 4 p.m. on October 14, 2011, but
could change depending on the actual time
spent on each agenda item. Each speaker will
be permitted 5 minutes for their presentation.
Interested individuals and representatives of
organizations are requested to notify Dr.
Martin H. Goldrosen, National Center for
Complementary and Alternative Medicine,
NIH, 6707 Democracy Boulevard, Suite 401,
Bethesda, Maryland 20892, 301–594–2014,
Fax: 301–480–9970. Letters of intent to
present comments, along with a brief
description of the organization represented,
should be received no later than 5 p.m. on
October 6, 2011. Only one representative of
an organization may present oral comments.
Any person attending the meeting who does
not request an opportunity to speak in
advance of the meeting may be considered
for oral presentation, if time permits, and at
the discretion of the Chairperson. In
addition, written comments may be
submitted to Dr. Martin H. Goldrosen at the
address listed above up to ten calendar days
(October 24, 2011) following the meeting.
Copies of the meeting agenda and the
roster of members will be furnished upon
request by contacting Dr. Martin H.
Goldrosen, Executive Secretary, NACCAM,
National Center for Complementary and
Alternative Medicine, National Institutes of
Health, 6707 Democracy Boulevard, Suite
401, Bethesda, Maryland 20892, 301–594–
2014, Fax 301–480–9970, or via e-mail at
naccames@mail.nih.gov.
VerDate Mar<15>2010
18:00 Sep 02, 2011
Jkt 223001
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nccam.nih.gov/about/naccam, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.701, ARRA Related
Biomedical Research and Research Support
Awards; 93.213, Research and Training in
Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: August 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–22695 Filed 9–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group, Microbiology and Infectious Diseases
Research Committee.
Date: October 4, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Michelle M. Timmerman,
PhD, Scientific Review Officer, Scientific
Review Program, DEA/NIAID/NIH/DHHS,
Room 2217, 6700B Rockledge Drive, MSC–
7616, Bethesda, MD 20892–7616, 301–451–
4573, timmermanm@niaid.nih.gov.
PO 00000
Frm 00077
Fmt 4703
Sfmt 9990
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–22697 Filed 9–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
COBRE III.
Date: October 25–26, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Steven Birken, PhD,
Scientific Revew Officer, Office of Review,
National Center for Research Resources,
National Institutes of Health, 6701
Democracy Blvd., Dem. 1, Room 1078, MSC
4874, Bethesda, MD 20892–4874, 301–435–
0815, birkens@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333; 93.702, ARRA Related
Construction Awards, National Institutes of
Health, HHS)
Dated: August 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–22700 Filed 9–2–11; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\06SEN1.SGM
06SEN1
]]>Agencies
[Federal Register Volume 76, Number 172 (Tuesday, September 6, 2011)]
[Notices]
[Pages 55073-55074]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-22695]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Complementary & Alternative Medicine; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the National
Advisory Council for Complementary and Alternative Medicine (NACCAM)
meeting.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections
[[Page 55074]]
552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant
applications and/or contract Proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications and/or contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory Council for Complementary
and Alternative Medicine.
Date: October 14, 2011.
Closed: October 14, 2011, 8:30 to 10:30 a.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Open: October 14, 2011, 11 a.m. to 4 p.m.
Agenda: Opening remarks by the Director of the National Center
for Complementary and Alternative Medicine, presentation of a new
research initiative, and other business of the Council.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen, PhD, Executive Secretary,
Director, Division of Extramural Activities, National Center for
Complementary and Alternative Medicine, National Institutes of
Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301)
594-2014.
The public comments session is scheduled from 3:30 to 4 p.m. on
October 14, 2011, but could change depending on the actual time
spent on each agenda item. Each speaker will be permitted 5 minutes
for their presentation. Interested individuals and representatives
of organizations are requested to notify Dr. Martin H. Goldrosen,
National Center for Complementary and Alternative Medicine, NIH,
6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301-
594-2014, Fax: 301-480-9970. Letters of intent to present comments,
along with a brief description of the organization represented,
should be received no later than 5 p.m. on October 6, 2011. Only one
representative of an organization may present oral comments. Any
person attending the meeting who does not request an opportunity to
speak in advance of the meeting may be considered for oral
presentation, if time permits, and at the discretion of the
Chairperson. In addition, written comments may be submitted to Dr.
Martin H. Goldrosen at the address listed above up to ten calendar
days (October 24, 2011) following the meeting.
Copies of the meeting agenda and the roster of members will be
furnished upon request by contacting Dr. Martin H. Goldrosen,
Executive Secretary, NACCAM, National Center for Complementary and
Alternative Medicine, National Institutes of Health, 6707 Democracy
Boulevard, Suite 401, Bethesda, Maryland 20892, 301-594-2014, Fax
301-480-9970, or via e-mail at naccames@mail.nih.gov.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://www.nccam.nih.gov/about/naccam, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.701, ARRA
Related Biomedical Research and Research Support Awards; 93.213,
Research and Training in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: August 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-22695 Filed 9-2-11; 8:45 am]
BILLING CODE 4140-01-P
